Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Current Assets (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Current Assets for 11 consecutive years, with $527.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets fell 17.53% to $527.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $527.7 million, a 17.53% decrease, with the full-year FY2025 number at $527.7 million, down 17.53% from a year prior.
  • Current Assets was $527.7 million for Q4 2025 at Intellia Therapeutics, down from $581.9 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $1.2 billion in Q4 2022 to a low of $495.9 million in Q2 2025.
  • A 5-year average of $776.3 million and a median of $792.0 million in 2021 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: soared 122.82% in 2021, then plummeted 37.63% in 2025.
  • Intellia Therapeutics' Current Assets stood at $769.3 million in 2021, then soared by 58.17% to $1.2 billion in 2022, then dropped by 17.95% to $998.3 million in 2023, then tumbled by 35.91% to $639.9 million in 2024, then decreased by 17.53% to $527.7 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Current Assets are $527.7 million (Q4 2025), $581.9 million (Q3 2025), and $495.9 million (Q2 2025).